| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
Purity: ≥98%
| Targets |
Lavendustin C targets multiple kinases. It is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It also inhibits Ca2+/calmodulin-dependent protein kinase II (CaMK II) with an IC50 of 0.2 µM.
|
|---|---|
| ln Vitro |
Strong inhibitory activity is exhibited by lavendustin C (compound 5), which may be the fundamental structure that inhibits tyrosine kinases [1]. Tyrosine kinase-related neutrophil degranulation and superoxide generation are inhibited by lavendustin C (10-150 µM) [3].
In vitro, Lavendustin C is a potent inhibitor of tyrosine kinase and CaMK II. It inhibits the kinase activity of EGFR and CaMK II. |
| ln Vivo |
Specific in vivo activity data for Lavendustin C is not detailed in the search results. Its activity as a kinase inhibitor suggests it may have effects on cell proliferation and signaling in vivo.
|
| Enzyme Assay |
The assay for kinase inhibition involves incubating the kinase (EGFR or CaMK II) with a substrate peptide and ATP in the presence of varying concentrations of Lavendustin C. The phosphorylation of the substrate is measured, often using a radiolabeled phosphate or a phospho-specific antibody.
|
| Cell Assay |
Cellular assays for Lavendustin C involve culturing cells that express EGFR or CaMK II. Cells are treated with the compound, and the phosphorylation of downstream targets is measured by Western blot. Inhibition of cell proliferation can also be assessed.
|
| Animal Protocol |
In vivo studies for Lavendustin C are not described in the search results. As a research compound, its effects are primarily studied in cellular models.
|
| ADME/Pharmacokinetics |
Lavendustin C has a molecular weight of 275.26 g/mol and a molecular formula of C14H13NO5. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Lavendustin C is not available in the search results. As a research chemical, standard safety precautions should be taken.
|
| References |
|
| Additional Infomation |
5-[(2,5-dihydroxyphenyl)methylamino]-2-hydroxybenzoic acid is an aromatic amine. Lavenderin C has been reported in the hairy-headed insect Elephantopus mollis, Streptomyces, and other organisms with relevant data. Lavenderin C is a compound that inhibits calmodulin kinase II and p60. (NCI)
Lavendustin C is a research tool used to study tyrosine kinase and CaMK II signaling pathways. It is not a pharmaceutical drug. |
| Molecular Formula |
C14H13NO5
|
|---|---|
| Molecular Weight |
275.26
|
| Exact Mass |
275.079
|
| CAS # |
125697-93-0
|
| Related CAS # |
125697-93-0;
|
| PubChem CID |
3896
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
597.5±50.0 °C at 760 mmHg
|
| Melting Point |
193-195ºC dec.
|
| Flash Point |
315.2±30.1 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.759
|
| LogP |
1.74
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
20
|
| Complexity |
338
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C(O)C1=CC(NCC2=CC(O)=CC=C2O)=CC=C1O
|
| InChi Key |
LULATDWLDJOKCX-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H13NO5/c16-10-2-4-12(17)8(5-10)7-15-9-1-3-13(18)11(6-9)14(19)20/h1-6,15-18H,7H2,(H,19,20)
|
| Chemical Name |
5-[[(2,5-dihydroxyphenyl)methyl]amino]-2-hydroxy-benzoic acid
|
| Synonyms |
Lavendustin C HDBA, NSC 666251.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ~100 mg/mL (~363.3 mM; with ultrasonication)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (9.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (9.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (9.08 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (25.0 mg/mL) to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.6329 mL | 18.1646 mL | 36.3293 mL | |
| 5 mM | 0.7266 mL | 3.6329 mL | 7.2659 mL | |
| 10 mM | 0.3633 mL | 1.8165 mL | 3.6329 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA